Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Infusiones de oxaliplatino de 2 versus 6 horas en pacientes con cánceres gastrointestinales

11 de noviembre de 2026 actualizado por: Olumide Gbolahan, Emory University

Evaluación de fase II del efecto de infusiones de oxaliplatino de 2 versus 6 horas sobre la neuropatía y la farmacocinética en pacientes con cánceres gastrointestinales

This phase II trial studies how well giving oxaliplatin over 6 hours works in treating nerve damage in patients with gastrointestinal cancers. Oxaliplatin can cause side effects such as nerve damage that may delay or reduce the dose of oxaliplatin. Giving oxaliplatin over a longer period of time (6 hours) may prevent or delay the development of nerve damage, which may keep patients on standard doses of chemotherapy longer, without having to delay treatment.

Descripción general del estudio

Descripción detallada

PRIMARY OBJECTIVE:

I. To determine the effect of 2 versus 6-hour oxaliplatin infusion time on the difference in severity of sensory neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treatment of Cancer (EORTC) chemotherapy-induced peripheral neuropathy (CIPN-20) scale at the initiation of cycle 4.

SECONDARY OBJECTIVES:

I. Pharmacokinetic parameters of maximum concentration (Cmax), area under the curve (AUC), time of maximum concentration (tmax), clearance, and half life (t1/2) of platinum ultra-filtrate.

II. CIPN-20 sensory score changes over the duration of therapy as measured by a cumulative area-under-the curve score.

III. Clinical outcomes including duration of therapy, oxaliplatin dose reductions, delays in therapy, and overall dose intensity and delivery of oxaliplatin.

IV. Relationship between oxaliplatin Cmax, patient-reported acute neurotoxicity, and chronic neurotoxicity by CIPN-20 scores.

OUTLINE: Patients are randomized to 1 of 2 groups.

2-hour infusion group: Patients receive oxaliplatin intravenously (IV) and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

6-hour infusion group: Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1, 3, 6, 12, and 18 months.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Olumide B. Gbolahan, MBBS, MSc
  • Número de teléfono: 404-778-0032
  • Correo electrónico: ogbolah@emory.edu

Ubicaciones de estudio

    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Reclutamiento
        • Emory University Hospital/Winship Cancer Institute
        • Contacto:
        • Investigador principal:
          • Olumide B. Gbolahan, MBBS, MSc
      • Atlanta, Georgia, Estados Unidos, 30308
        • Reclutamiento
        • Emory University Hospital Midtown
        • Contacto:
        • Investigador principal:
          • Olumide B. Gbolahan, MBBS, MSc
      • Atlanta, Georgia, Estados Unidos, 30342
        • Reclutamiento
        • Emory Saint Joseph's Hospital
        • Investigador principal:
          • Olumide B. Gbolahan, MBBS, MSc
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Confirmed diagnosis of a gastrointestinal cancer
  • Plan for 4 or more cycles of FOLFOX6 (fluorouracil [with leucovorin] and oxaliplatin) containing chemotherapy
  • Histologically confirmed, measurable or evaluable disease. Patients with advanced or metastatic disease should have at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Patients in the adjuvant treatment setting planned to have > 4 cycles of FOLFOX-containing chemotherapy are eligible and will be followed per standard of care
  • Absolute neutrophil count (ANC) ≥ 1,500/µL (no white blood cell growth factors allowed to meet requirement)
  • Platelets ≥ 75,000/µL (may be transfused up to 72 hours prior to day 1 to meet requirement)
  • Hemoglobin ≥ 8 g/dL (may be transfused up to 72 hours prior to day 1 to meet requirement)
  • Creatinine clearance > 30 mL/min by Cockcroft-Gault, to preserve similar dosing (85 mg/m²) for analysis
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
  • Signed informed consent
  • Adequate birth control when appropriate

Exclusion Criteria:

  • Any preexisting grade 2 or higher peripheral neuropathy

  • Patients currently receiving anticancer therapies or who have received any focal or systemic anticancer therapy within 14days of the start of FOLFOX6

  • Known intolerance or hypersensitivity to any agent in FOLFOX6 or concurrent agents

  • Patients who have any known severe and/or uncontrolled medical conditions such as:

    • Unstable angina pectoris, symptomatic heart failure; (New York Heart Association class III or IV), myocardial infarction ≤ 6 months prior, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease
    • Active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, or decompensated liver disease
  • Patients with any history of severe hemorrhage requiring ≥ 4 units of packed red blood cells (RBCs) in a 48-hour period

  • Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study

  • Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 14days prior to dosing

  • Pregnant or nursing (lactating) women

  • Women of childbearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during the study and 8 weeks after. Highly effective contraception methods include combination of any two of the following:

    • Use of oral, injected or implanted hormonal methods of contraception or;
    • Placement of an intrauterine device (IUD) or intrauterine system (IUS);
    • Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository;
    • Total abstinence or;
    • Male/female sterilization Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: 2-hour infusion group

Patients receive oxaliplatin IV and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

Given IV

Otros nombres:
  • 5-FU
  • Carac
  • Ribofluor

Given IV

Otros nombres:
  • Eloxatina

Given IV

Otros nombres:
  • Ácido folínico
Experimental: 6-hour infusion group

Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

Given IV

Otros nombres:
  • 5-FU
  • Carac
  • Ribofluor

Given IV

Otros nombres:
  • Eloxatina

Given IV

Otros nombres:
  • Ácido folínico

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Effect of 2 versus 6-hour oxaliplatin infusion time on neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treatment of Cancer (EORTC) chemotherapy-induced peripheral neuropathy (CIPN-20) scale
Periodo de tiempo: Baseline up to 60 days (course 4)

The EORTC-CIPN-20 sub-scales will be computed according to the standard scoring algorithm and then transformed to a 0 to 100 scale, where high scores mean less symptom burden. The primary outcome measure of difference in sensory scores of the two groups between baseline and the initiation of cycle 4 will be the driver of the analysis.

Baseline up to 60 days (course 4)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Maximum concentrations achieved (Cmax)
Periodo de tiempo: At baseline and at 1, 2, 4, 6, 48, and 192 hours after initiation of oxaliplatin

The study will focus on maximum concentrations achieved (Cmax) with each infusion time. Data will be analyzed using non-compartmental methods via Phoenix WinNonlin analytical software, version 8.0 or higher.

At baseline and at 1, 2, 4, 6, 48, and 192 hours after initiation of oxaliplatin
Changes in tumor size
Periodo de tiempo: Up to 18 months after completion or discontinuation of chemotherapy

The study will assess changes in tumor size per standard of care assessments at screening and every 2 months.

Up to 18 months after completion or discontinuation of chemotherapy
Duration of therapy
Periodo de tiempo: Up to 18 months after completion or discontinuation of chemotherapy

Duration of therapy will be recorded.

Up to 18 months after completion or discontinuation of chemotherapy
Dose density
Periodo de tiempo: Up to 18 months after completion or discontinuation of chemotherapy

Dose density will be recorded.

Up to 18 months after completion or discontinuation of chemotherapy
Frequency of dose holds or reductions
Periodo de tiempo: Up to 18 months after completion or discontinuation of chemotherapy

Frequency of dose holds or reductions will be recorded.

Up to 18 months after completion or discontinuation of chemotherapy

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Olumide B. Gbolahan, MBBS, MSc, Emory University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

14 de marzo de 2019

Finalización primaria (Estimado)

5 de agosto de 2027

Finalización del estudio (Estimado)

17 de septiembre de 2028

Fechas de registro del estudio

Enviado por primera vez

9 de enero de 2019

Primero enviado que cumplió con los criterios de control de calidad

9 de enero de 2019

Publicado por primera vez (Actual)

11 de enero de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir